Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 3 (2008), Issue 6 (June)

1. Telomeric 3' overhangs in chronic HBV-related hepatitis and hepatocellular carcinoma.
   Int J Cancer, 123(2): 264-72. [Abstract] [Full-text]
2. Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance.
   J Subst Abuse Treat, 35(1): 78-86. [Abstract] [Full-text]
3. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
   Am J Respir Crit Care Med, 177(12): 1391-6. [Abstract] [Full-text]
4. Management of chronic hepatitis C virus infection in HIV-infected patients.
   Clin Infect Dis, 47(1): 94-101. [Abstract] [Full-text]
5. Factors influencing Hepatitis C virus sero-prevalence among blood donors in north west Pakistan.
   J Public Health Policy, 29(2): 207-25. [Abstract] [Full-text]
6. Characteristics of hepatitis B virus genotype G coinfected with genotype H in chimeric mice carrying human hepatocytes.
   Virology, 376(2): 408-15. [Abstract] [Full-text]
7. Hepatitis C virus infection in mouse hepatoma cells co-expressing human CD81 and Sip-L.
   Biochem Biophys Res Commun, 372(1): 157-61. [Abstract] [Full-text]
8. Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death.
   Virology, 376(2): 397-407. [Abstract] [Full-text]
9. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.
   Clin Infect Dis, 46(12): 1852-8. [Abstract] [Full-text]
10. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
    J Virol, 82(13): 6644-53. [Abstract] [Full-text]
11. APOBEC3-independent interferon-induced viral clearance in hepatitis B virus transgenic mice.
    J Virol, 82(13): 6585-90. [Abstract] [Full-text]
12. Dynamics of an HBV model with diffusion and delay.
    J Theor Biol, 253(1): 36-44. [Abstract] [Full-text]
13. Potential hepatoprotective effects of new Cuban natural products in rat hepatocytes culture.
    Toxicol In Vitro, 22(5): 1242-9. [Abstract] [Full-text]
14. Molecular characterization and phylogenetic analysis of the complete genome of a hepatitis E virus from European swine.
    Virus Genes, 37(1): 39-48. [Abstract] [Full-text]
15. Classification of duck hepatitis virus into three genotypes based on molecular evolutionary analysis.
    Virus Genes, 37(1): 52-9. [Abstract] [Full-text]
16. Hepatocellular carcinoma and other primary liver cancers in hepatitis C patients in Sweden - a low endemic country.
    J Viral Hepat, 15(7): 531-7. [Abstract] [Full-text]
17. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study.
    J Viral Hepat, 15(7): 538-50. [Abstract] [Full-text]
18. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    J Viral Hepat, 15(7): 475-81. [Abstract] [Full-text]
19. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C.
    J Viral Hepat, 15(7): 498-507. [Abstract] [Full-text]
20. Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease.
    J Viral Hepat, 15(7): 515-22. [Abstract] [Full-text]
21. Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C.
    J Viral Hepat, 15(7): 523-30. [Abstract] [Full-text]
22. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
    J Viral Hepat, 15(7): 482-9. [Abstract] [Full-text]
23. Relationship of peripheral blood CD4-positive T cells to carcinogenesis in patients with HCV-related chronic hepatitis and liver cirrhosis.
    Cancer Chemother Pharmacol, 62(3): 401-6. [Abstract] [Full-text]
24. Hepatobiliary and pancreatic MRI and MRCP findings in patients with HIV infection.
    AJR Am J Roentgenol, 191(1): 228-32. [Abstract] [Full-text]
25. Hepatitis B virus, hepatitis C virus and other blood-borne infections in healthcare workers: guidelines for prevention and management in industrialised countries.
    Occup Environ Med, 65(7): 446-51. [Abstract] [Full-text]
26. Hepatitis B vaccination in travelers.
    Expert Rev Vaccines, 7(5): 673-7. [Abstract] [Full-text]
27. Hepatitis A vaccines.
    Expert Rev Vaccines, 7(5): 535-45. [Abstract] [Full-text]
28. Investigation of hepatitis E virus infection in swine from Hunan province, China.
    J Med Virol, 80(8): 1391-6. [Abstract] [Full-text]
29. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    J Med Virol, 80(8): 1363-9. [Abstract] [Full-text]
30. Concomitant diffuse large B-cell lymphoma and hepatocellular carcinoma in chronic hepatitis C virus liver disease: a study of two cases.
    J Med Virol, 80(8): 1350-3. [Abstract] [Full-text]
31. Multiple surface antigen mutations in five blood donors with occult hepatitis B virus infection.
    J Med Virol, 80(8): 1344-9. [Abstract] [Full-text]
32. Hepatitis B virus X mutations occurring naturally associated with clinical severity of liver disease among Korean patients with chronic genotype C infection.
    J Med Virol, 80(8): 1337-43. [Abstract] [Full-text]
33. Cross-species infection of specific-pathogen-free pigs by a genotype 4 strain of human hepatitis E virus.
    J Med Virol, 80(8): 1379-86. [Abstract] [Full-text]
34. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study).
    J Med Virol, 80(8): 1332-6. [Abstract] [Full-text]
35. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
    Clin Immunol, 128(1): 46-56. [Abstract] [Full-text]
36. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.
    Mol Pharmacol, 74(1): 20-33. [Abstract] [Full-text]
37. An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases.
    Hum Pathol, 39(7): 1103-10. [Abstract] [Full-text]
38. An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models.
    Mol Ther, 16(7): 1316-22. [Abstract] [Full-text]
39. L-Gln and L-Ser suppress the D-galactosamine-induced IL-18 expression and hepatitis.
    Biochem Biophys Res Commun, 372(4): 688-90. [Abstract] [Full-text]
40. The pervading influence of alcoholic liver disease in hepatology.
    Alcohol Alcohol, 43(4): 393-7. [Abstract] [Full-text]
41. The case for combination antiviral therapy for chronic hepatitis B virus infection.
    Lancet Infect Dis, 8(7): 444-8. [Abstract] [Full-text]
42. Aberrant lymphocyte activation precedes delayed virus-specific T-cell response after both primary infection and secondary exposure to hepadnavirus in the woodchuck model of hepatitis B virus infection.
    J Virol, 82(14): 6992-7008. [Abstract] [Full-text]
43. Cryofibrinogen in patients with hepatitis C virus infection.
    Am J Med, 121(7): 624-31. [Abstract] [Full-text]
44. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort.
    Am J Obstet Gynecol, 199(1): 38.e1-9. [Abstract] [Full-text]

© 2006-2008 Hepatitis Research Today. All Rights Reserved.